Ionis Pharmaceuticals (IONS) Total Non-Current Liabilities (2010 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Total Non-Current Liabilities of $2.5 billion for Q2 2026, up 10.11% year-over-year from $2.3 billion in Q2 2025, and down 13.79% quarter-over-quarter from $2.9 billion in Q1 2026.
Ionis Pharmaceuticals (IONS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $2.5 billion for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 10.11% year-over-year to $2.5 billion; the TTM figure through Jun 2026 stood at $2.5 billion (up 10.11% YoY), while the FY2025 annual figure was $3.0 billion, up 27.22% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $2.5 billion, down from $2.9 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $3.0 billion in Q4 2025, with the low at $1.9 billion in Q3 2024.
- The 5-year median for Total Non-Current Liabilities is $2.1 billion (2023), against an average of $2.2 billion.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities retreated 10.7% in 2024, then grew 28.43% in 2026.
- Ionis Pharmaceuticals' Total Non-Current Liabilities stood at $2.0 billion in 2022, then grew by 6.56% to $2.1 billion in 2023, then grew by 13.1% to $2.4 billion in 2024, then rose by 27.22% to $3.0 billion in 2025, then declined by 15.97% to $2.5 billion in 2026.
- Business Quant data shows IONS's Total Non-Current Liabilities at $2.5 billion in Q2 2026, $2.9 billion in Q1 2026, and $3.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | 2.53 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.53 Bn |
| Mar 31, 2026 | 2.93 Bn |
| Dec 31, 2025 | 3.01 Bn |
| Sep 30, 2025 | 2.39 Bn |
| Jun 30, 2025 | 2.29 Bn |
| Mar 31, 2025 | 2.28 Bn |
| Dec 31, 2024 | 2.36 Bn |
| Sep 30, 2024 | 1.88 Bn |
| Jun 30, 2024 | 1.89 Bn |
| Mar 31, 2024 | 1.94 Bn |
| Dec 31, 2023 | 2.09 Bn |
| Sep 30, 2023 | 2.11 Bn |
| Jun 30, 2023 | 2.03 Bn |
| Mar 31, 2023 | 1.89 Bn |
| Dec 31, 2022 | 1.96 Bn |
| Dec 31, 2021 | 1.83 Bn |
| Dec 31, 2017 | 957.49 Mn |
| Sep 30, 2017 | 854.89 Mn |
| Jun 30, 2017 | 824.24 Mn |
| Mar 31, 2017 | 809.79 Mn |